Individualized Cancer Treatment: Merck/Moderna's Personalized Skin Cancer Therapy Enters Late-Stage Of Development
Portfolio Pulse from Vandana Singh
Merck & Co Inc and Moderna Inc have initiated a Phase 3 trial for V940 (mRNA-4157), a personalized skin cancer therapy. The trial will enroll approximately 1,089 patients, with the first patients now enrolling in Australia. The therapy has been granted Breakthrough Therapy Designation by the FDA and the Priority Medicines scheme by the European Medicines Agency. The companies also plan to expand the development program to additional tumor types.
July 26, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck has initiated a Phase 3 trial for a personalized skin cancer therapy, which could potentially boost its product portfolio and revenues if successful.
The initiation of the Phase 3 trial for the personalized skin cancer therapy could potentially boost Merck's product portfolio and revenues if the trial is successful. This is a significant development for the company and could have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna has initiated a Phase 3 trial for a personalized skin cancer therapy, which could potentially boost its product portfolio and revenues if successful.
The initiation of the Phase 3 trial for the personalized skin cancer therapy could potentially boost Moderna's product portfolio and revenues if the trial is successful. This is a significant development for the company and could have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100